| Edaravone (+) | Edaravone (–) | P value | |
|---|---|---|---|
| (n=34) | (n=10) | ||
| Age | 71 | 71 | 0.094 |
| Male/female | 21/13 | 5/5 | 0.716 |
| Stroke subtypes | |||
| LAC/AT/CE (n) | 7/16/11 | 2/6/2 | 0.719 |
| Risk factors for arteriosclerosis | |||
| Hypertension, % (n) | 56 (19) | 80 (8) | 0.271 |
| Diabetes mellitus, % (n) | 18 (6) | 30 (3) | 0.402 |
| Hyperlipidemia, % (n) | 44 (15) | 10 (1) | 0.067 |
| Atrial fibrillation, % (n) | 33 (12) | 40 (4) | 1 |
| Time from onset to arrival (h) | 9.5 | 30.3 | 0.037 |
| Baseline NIHSS (range) | 11.1 (2-37) | 6.1 (1-9) | 0.842 |
| NIHSS 14 days after admission (range) | 6.3 (0-28) | 3 (1-8) | 0.644 |
| mRS at discharge | 2.5 | 2.7 | 0.597 |
| Medications | |||
| Antithrombotic, % (n) | 44 (15) | 80 (8) | 0.076 |
| Glycerol, % (n) | 86 (29) | 60 (6) | 0.175 |
| Length of stay (days) | 32 | 29.7 | 0.123 |
| Δ8-OHdG (%) | 20.8 | 21.3 | 0.777 |